IN2014CN04615A - - Google Patents

Info

Publication number
IN2014CN04615A
IN2014CN04615A IN4615CHN2014A IN2014CN04615A IN 2014CN04615 A IN2014CN04615 A IN 2014CN04615A IN 4615CHN2014 A IN4615CHN2014 A IN 4615CHN2014A IN 2014CN04615 A IN2014CN04615 A IN 2014CN04615A
Authority
IN
India
Prior art keywords
human ctgf
anti human
seq
amino acid
acid sequence
Prior art date
Application number
Other languages
English (en)
Inventor
Shoji Iwasaki
Ryuichi Moriya
Masayasu Yoshino
Koji Takakura
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of IN2014CN04615A publication Critical patent/IN2014CN04615A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4615CHN2014 2011-12-22 2012-12-21 IN2014CN04615A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011281811 2011-12-22
PCT/JP2012/083206 WO2013094723A1 (ja) 2011-12-22 2012-12-21 新規抗ヒトctgf抗体

Publications (1)

Publication Number Publication Date
IN2014CN04615A true IN2014CN04615A (enExample) 2015-09-18

Family

ID=48668601

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4615CHN2014 IN2014CN04615A (enExample) 2011-12-22 2012-12-21

Country Status (16)

Country Link
US (1) US9587015B2 (enExample)
EP (1) EP2796550B1 (enExample)
JP (1) JP6040943B2 (enExample)
KR (1) KR20140107507A (enExample)
CN (1) CN104011206B (enExample)
AR (1) AR089425A1 (enExample)
BR (1) BR112014015405A2 (enExample)
CA (1) CA2859627A1 (enExample)
EA (1) EA029290B1 (enExample)
ES (1) ES2665851T3 (enExample)
IN (1) IN2014CN04615A (enExample)
MX (1) MX345019B (enExample)
PL (1) PL2796550T3 (enExample)
PT (1) PT2796550T (enExample)
TW (1) TW201333034A (enExample)
WO (1) WO2013094723A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
EP3981787A4 (en) * 2019-06-04 2022-09-14 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODIES AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS USE
CN116391041A (zh) * 2020-12-03 2023-07-04 江苏恒瑞医药股份有限公司 一种含抗结缔组织生长因子抗体的药物组合物
EP4537841A1 (en) 2022-06-07 2025-04-16 Astellas Pharma, Inc. Pharmaceutical composition containing anti-integrin alpha-11 antibody for treatment or prevention of aging-related diseases
KR20250097820A (ko) 2022-10-31 2025-06-30 아스텔라스세이야쿠 가부시키가이샤 Toll양 수용체 7/8 듀얼 아고니스트 화합물을 포함하는 항체 약물 복합체
WO2024188179A1 (zh) * 2023-03-10 2024-09-19 上海济煜医药科技有限公司 一种靶向ctgf的抗体或其抗原结合片段及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8808645U1 (de) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen Anzeigeeinrichtung für Feuerlöscher
US6114143A (en) 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
JP4537507B2 (ja) 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
CN1660911A (zh) 1998-12-14 2005-08-31 迈阿密大学 结缔组织生长因子片段及其方法和用途
US7115390B1 (en) 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2009067678A (ja) 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
AR089425A1 (es) 2014-08-20
PL2796550T3 (pl) 2018-08-31
PT2796550T (pt) 2018-04-18
EP2796550B1 (en) 2018-02-28
EA201491240A1 (ru) 2014-11-28
EA029290B1 (ru) 2018-03-30
CA2859627A1 (en) 2013-06-27
KR20140107507A (ko) 2014-09-04
MX345019B (es) 2017-01-11
BR112014015405A2 (pt) 2017-06-13
US20140343258A1 (en) 2014-11-20
US9587015B2 (en) 2017-03-07
WO2013094723A1 (ja) 2013-06-27
CN104011206B (zh) 2017-03-08
MX2014007681A (es) 2014-11-25
JPWO2013094723A1 (ja) 2015-04-27
EP2796550A4 (en) 2015-08-19
CN104011206A (zh) 2014-08-27
EP2796550A1 (en) 2014-10-29
ES2665851T3 (es) 2018-04-27
TW201333034A (zh) 2013-08-16
JP6040943B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
NZ610734A (en) Human antibodies to the glucagon receptor
WO2009048537A3 (en) Humanized antibody
NZ706377A (en) Il-6 antagonists and uses thereof
SI2771031T1 (en) Humanized antibodies that recognize alpha-synuclein
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
MX345019B (es) Nuevo anticuerpo ctgf antihumano.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
PH12014500167A1 (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
EA201490433A1 (ru) Новое антитело против ngf человека
EA033387B1 (ru) СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
NZ610091A (en) Antibodies
WO2013120012A3 (en) Cdim binding proteins and uses thereof
RU2013140625A (ru) Антитела против ангиопоэтина-2 человека
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
MX2013011414A (es) Novedoso anticuerpo anti-receptor de il-23 humano.
PH12013501456A1 (en) Use of anti~amyloid beta antibody